Some changes have been significant, such as a move to greater emphasis on antibiotic prescribing for urinary tract infection as of 2018/2019.28 Furthermore, as the QP is awarded retrospectively and is contingent on meeting other financial targets, the funding mechanism is not guaranteed, making it difficult to engage commissioners and to create a firm financial framework to underpin CRP implementation. This evidence concerns the gene CRP and urinary tract infection.